This Article Full Text (PDF) All Versions of this Article: 0269881107083639v1 22/2/187    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Verrico, C. D Articles by Madras, B. K Search for Related Content PubMed PubMed Citation Articles by Verrico, C. D Articles by Madras, B. K Social Bookmarking                   What's this?

MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor

Department of Psychiatry, Harvard Medical School and Division of Neurochemistry, New England Primate Research Center, Southborough, MA 01772-9102, USA

Laurie Lynch

Department of Psychiatry, Harvard Medical School and Division of Neurochemistry, New England Primate Research Center, Southborough, MA 01772-9102, USA

Michele A Fahey

Department of Psychiatry, Harvard Medical School and Division of Neurochemistry, New England Primate Research Center, Southborough, MA 01772-9102, USA

Ashley-Kay Fryer

Department of Psychiatry, Harvard Medical School and Division of Neurochemistry, New England Primate Research Center, Southborough, MA 01772-9102, USA

Gregory M Miller

Department of Psychiatry, Harvard Medical School and Division of Neurochemistry, New England Primate Research Center, Southborough, MA 01772-9102, USA

Bertha K Madras

Department of Psychiatry, Harvard Medical School and Division of Neurochemistry, New England Primate Research Center, Southborough, MA 01772-9102, USA, bertha_madras{at}hms.harvard.edu

Human MDMA (R,S-3,4-methylenedioxymethamphetamine) users display selective cognitive deficits after acute MDMA exposure, frequently attributed to serotonin deficits. We postulated that MDMA will compromize executive function in primates and that an inhibitor of the serotonin transporter (SERT) and the norepinephrine transporter (NET) but not the dopamine (DAT) transporter, will prevent impairment. The potencies of DAT/NET, NET and SERT inhibitors to block transport of [³H]MDMA and [³H]monoamines were compared in vitro. Subsequently, cynomolgus monkeys (Macaca fasicularis) were trained to stable performance in a reversal learning task. Effects of once-weekly oral or i.m. dose of MDMA (1.5 mg/kg, n = 4) on performance were monitored, alone or after pretreatment with inhibitors of the SERT, DAT or NET (prior to i.m. MDMA). 1) Drug potencies for blocking [³H]MDMA or [³H]monoamine transport were not consistent; 2) Oral MDMA increased error rates in a cognitive task for up to three days following exposure, whereas intramuscular MDMA prevented subjects from performing the cognitive task on the day of administration, but not on subsequent days; 3) The SERT inhibitor citalopram and the NET inhibitor desipramine, but not the DAT/NET inhibitor methylphenidate, reversed the effects of MDMA on task performance and mandibular movements induced by i.m. MDMA and 4) MDMA altered sleep latency. Oral MDMA impairs executive function in monkeys for several days, a finding of potential relevance to MDMA consumption by humans. Reversal of impaired executive function by a NET inhibitor implicates the NET and norepinephrine in MDMA-induced cognitive impairment and may be relevant to therapeutic strategies.

Key Words: MDMA • rhesus monkey • monoamine transporter • cognition • aversion • inhibitor • impairment

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?